SK Bioscience Terminates High-Efficiency Influenza Vaccine Production Technology Transfer Agreement

[Asia Economy Reporter Gong Byung-sun] SK Bioscience announced on the 9th that Sanofi Pasteur, the vaccine subsidiary of the Sanofi Group, has notified the termination of the technology transfer agreement for high-efficiency influenza vaccine production using cell culture method, which was signed on February 12, 2018.

The agreement was signed before SK Bioscience was spun off from SK Chemicals.